<DOC>
	<DOC>NCT01673724</DOC>
	<brief_summary>The purpose of this study is to determine whether pramipexole and bromocriptine are effective in the treatment of non-motor symptoms in Parkinson's Disease.</brief_summary>
	<brief_title>Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease</brief_title>
	<detailed_description>PRIMARY OBJECTIVE Evaluate the Improvement of Nonmotor symptom scale (NMSS) between Pramipexole and Bromocriptine for early Parkinson's disease during 24-week treatment SECONDARY OBJECTIVE - Evaluate the improvement for Depression which is one of the Nonmotor symptoms - Evaluate the improvement of clinical symptoms between two groups - Evaluate the improvement of Quality of Life between two groups</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<criteria>Parkinson's disease patients in accordance with UK Queensquare Brain Bank modified Hoehn &amp; Yahr stage &lt;3 Dopamine agents(Levodopa, dopamine agonists) naive patients, or the patients who have discontinued the agents at least four weeks before the screening in case of using the dopamine agents are administered before. KMMSE&lt;24 History of druginduced Parkinsonism secondary parkinsonism History of schizophrenia or hallucination Requirement of treatment with antidepressants due to depressive disorder Pregnant and/or breeding women Renal inadequacy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>